{
    "clinical_study": {
        "@rank": "87561", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if L-756423, an anti-HIV drug, is safe to give with\n      indinavir and if it works well at lowering the level of HIV in the blood (viral load)."
        }, 
        "brief_title": "A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken Indinavir", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "All patients receive L-756423 plus indinavir plus two licensed nucleoside reverse\n      transcriptase inhibitors (NRTIs), at least one to which the patient is naive. Patients\n      remain on the drug regimen for 12 weeks (with possible extension to 16 weeks). Patients are\n      evaluated with physical examinations and laboratory tests for blood and urine at Weeks 1, 2,\n      4, 6, 8, and 12 and two weeks post study.  Plasma viral RNA is measured at Weeks 1, 2, 4, 6,\n      8, and 12. CD4 cell counts are measured at Weeks 2,4,8, and 12."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this study if you:\n\n          -  Are HIV-positive.\n\n          -  Are at least 18 years old.\n\n          -  Have a viral load of at least 1,000 copies/ml.\n\n          -  Have a CD4 cell count of at least 100 cells/mm3.\n\n          -  Have experienced treatment failure (your viral load increased significantly) within\n             24 weeks of study entry while taking indinavir.\n\n        Exclusion Criteria\n\n        You will not be eligible for this study if you:\n\n          -  Are taking nonnucleoside reverse transcriptase inhibitors (NNRTIs)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "30", 
        "firstreceived_date": "January 17, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002452", 
            "org_study_id": "300A", 
            "secondary_id": "008-00"
        }, 
        "intervention": [
            {
                "intervention_name": "L-756423", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Indinavir", 
                "Reverse Transcriptase Inhibitors"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "Indinavir", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "Viral Load"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "352942050"
                    }, 
                    "name": "Univ of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }, 
                    "name": "Georgetown Univ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "AIDS Research Consortium of Atlanta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii", 
                        "zip": "96816"
                    }, 
                    "name": "Hawaii AIDS Clinical Trial Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "The CORE Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10011"
                    }, 
                    "name": "Cornell Clinical Trials Unit - Chelsea Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15261"
                    }, 
                    "name": "Pittsburgh Treatment Ctr / Univ of Pittsburgh"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Vanderbilt Univ Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multicenter, Open-Label, Pilot Study to Evaluate the Safety and Activity of L-756423/Indinavir Sulfate, 800/400 Mg b.i.d. in Combination With Two nRTIs in HIV-Infected Patients Who Failed an Indinavir Containing Regimen", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002452"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2000"
    }, 
    "geocoordinates": {
        "AIDS Research Consortium of Atlanta": "33.749 -84.388", 
        "Cornell Clinical Trials Unit - Chelsea Clinic": "40.714 -74.006", 
        "Georgetown Univ": "38.895 -77.036", 
        "Hawaii AIDS Clinical Trial Unit": "21.307 -157.858", 
        "Pittsburgh Treatment Ctr / Univ of Pittsburgh": "40.441 -79.996", 
        "The CORE Ctr": "41.878 -87.63", 
        "Univ of Alabama at Birmingham": "33.521 -86.802", 
        "Vanderbilt Univ Med Ctr": "36.166 -86.784"
    }
}